市場調查報告書
商品編碼
1433292
全球病患登記軟體市場 2023-2030Global Patient Registry Software Market 2023-2030 |
在預測期內(2023-2030年),全球病患登記軟體市場預計將以 8.6%的CAGR成長。該市場的成長歸功於全球以患者為中心的照護。除了患者倡導團體的參與之外,涵蓋患者報告的結果測量也反映了以患者為中心的護理日益成長的趨勢。這一轉變得到了患者登記軟體的幫助,該軟體捕捉患者的觀點和經驗。根據美國國立衛生研究院的資料,2023年 5月,患者登記涵蓋了廣泛的疾病領域,其中重點是歐洲。 92%的登記處涵蓋了臨床患者,81%的登記處獲得了知情同意,76%的登記處保護了收集到的資料。 57%的註冊中心收集了患者報告的結果指標,38%在註冊中心設計過程中諮詢了 PAG,51%報告了品質管理細節,46%報告了維護細節。
全球患者登記軟體市場按登記類型、軟體類型、部署和最終用戶進行細分。根據註冊類型,市場分為特定疾病註冊、健康服務註冊和產品註冊。根據軟體類型,市場分為獨立軟體和整合軟體。根據部署,市場分為本地和雲端。此外,根據最終用戶,市場又細分為醫院和衛生系統、政府組織和第三方管理機構(TPA)、製藥、生物技術和醫療器材公司等。政府組織和第三方管理機構(TPA)子類別預計將佔據最終用戶細分市場的很大一部分市場佔有率。這歸因於製藥、生物技術和醫療器材公司數量的增加,這主要是由於對製藥和生物技術產品的需求增加。
在註冊類型中,特定疾病註冊細分市場預計將在全球患者註冊軟體市場中佔據相當大的佔有率。根據 BMC 的說法,2022年 4月,疾病登記系統是一個用於收集、分析和報告特定人群患有相同病症的患者資料的資訊系統。它可用於醫療保健評估、發病率和盛行率估計、監測護理品質、提供回饋、觀察疾病的自然病程、監測臨床安全性以及評估疾病負擔、健康結果和成本。
全球病患登記軟體市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國和亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,由於慢性病的嚴重流行以及該地區進行的治療手術數量的增加,預計北美將在全球市場中佔據顯著佔有率。
在所有地區中,歐洲地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於該地區罕見疾病宣傳的不斷加強。對罕見疾病宣傳和認知的日益重視凸顯了孤兒病患者未得到滿足的醫療需求。患者登記處透過收集有關患者體驗的真實資料來幫助實現這些目標。根據 Frontiers 報道,2022年 8月,歐洲藥品管理局(EMA)評估的所有上市許可申請中,有 26.8%包括所謂的孤兒藥產品,這些產品目的是治療、預防或促進診斷危及生命或慢性衰弱的疾病,但在歐盟(EU),盛行率低於萬分之五。由於患者群體小且異質性,這些藥物往往受到有限的臨床證據的影響,而患者登記已被確定為應對這一挑戰並提供資料以支持監管決策的潛在方法。病患登記是一個有組織的系統,用於收集和組織患有某種疾病、狀況或暴露的人群的特定健康結果的資料。
服務全球病患登記軟體市場的主要公司包括 Dacima Software, Inc.、DSG, Inc.、FIGmd Inc.、Global Vision Technologies Image Trend Inc.、LexisNexis group、IBM Corp. 等。市場參與者透過各種策略(包括併購、夥伴關係、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2022年 4月,Quantori, LLC 推出了註冊科學實務。重點是為患者、醫生和研究人員開發註冊計劃。登記科學是醫學資訊學和生物統計學的新興領域,它將醫學和流行病學結合起來,追蹤長期健康結果並改善實證護理服務。
Global Patient Registry Software Market Size, Share & Trends Analysis Report by Type of Registry (Disease-Specific Registries, Health Service Registries, and Product Registries), by Type of Software (Stand-Alone Software, and Integrated Software), by Deployment (On-Premises, and Cloud), and by End-User (Hospitals and Health Systems, Government Organizations, and Third Party Administrators (TPAs), Pharmaceutical, Biotechnology, and Medical Device Companies, and Others) Forecast Period (2023-2030)
The global patient registry software market is anticipated to grow at a CAGR of 8.6% during the forecast period (2023-2030). The market's growth is attributed to patient-centered care across the globe. The inclusion of patient-reported outcome measures, in addition to the participation of patient advocacy groups, reflects an increasing tendency toward patient-centered care. This transition is aided by patient registry software, that captures patient viewpoints and experiences. According to the National Institute of Health, in May 2023,patient registries covered a wide range of disease areas, with a focus on Europe. 92% of the registries included clinical patients, 81% obtained informed consent, and 76% protected the collected data. 57% of the registries collected patient-reported outcome measures, 38% consulted PAGs during the registry design process, 51% reported quality management details, and 46% reported maintenance details.
The global patient registry software market is segmented on the type of registry, type of software, deployment, and end user. Based on the type of registry, the market is sub-segmented into disease-specific registries, health service registries, and product registries. Based on the type of software, the market is sub-segmented into stand-alone software, and integrated software. Based on the deployment, the market is sub-segmented into on-premises, and cloud. Further, on the basis of end-user, the market is sub-segmented into hospitals and health systems, government organizations and third-party administrators (TPAs), pharmaceutical, biotechnology, and medical device companies, and others. The government organizations and third party administrators (TPAs) subcategory is expected to capture a significant portion of the market share within the end-user segment. This is attributed to the number of pharmaceutical, biotechnology, and medical device companies has increased, owing essentially to increased demand for pharmaceutical and biotechnology products.
Among the type of registry, the disease-specific registries sub-segment is expected to hold a considerable share of the global patient registry software market. According to the BMC, in April 2022, a disease registry system is an information system used for collecting, analyzing, and reporting data about a certain population of patients with the same condition. It can be used for healthcare evaluation, estimation of incidence and prevalence, monitoring the quality of care, providing feedback, observing the natural course of diseases, monitoring clinical safety, and assessing disease burden, health outcomes, and costs.
The global patient registry software market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the significant prevalence of chronic diseases, in addition to an increase in the number of therapeutic operations conducted in the region.
Among all regions, the Europe regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising rare disease advocacy in the region. The growing emphasis on rare disease advocacy and awareness has highlighted to light the unmet medical requirements of patients suffering from orphan diseases. Patient registries help to accomplish these objectives by collecting real-world data on patient experiences. According to the Frontiers, in August 2022, 26.8% of all the marketing authorization applications assessed by the European Medicines Agency (EMA) were for so-called orphan medicinal products, that are meant to treat, prevent or facilitate diagnosis of diseases that are life-threatening or chronically debilitating, but have a prevalence of less than 5 in 10,000 in the European Union (EU). These medicines are often subject to limited clinical evidence owing to their small and heterogeneous patient populations, and patient registries have been identified as a potential way to address this challenge and provide data to support regulatory decision-making. A patient registry is an organized system that collects and organizes data on specified health outcomes for a population with a certain disease, condition or exposure.
The major companies serving the global patient registry software market include Dacima Software, Inc., DSG, Inc., FIGmd Inc., Global Vision Technologies Image Trend Inc., LexisNexis group, IBM Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Quantori, LLC, launched a Registry Science Practice. That focused on the development of registry programs for patients, physicians, and researchers. Registry Science is an emerging area of medical informatics and biostatistics that combines medicine and epidemiology to track long-term health outcomes and improve evidence-based care delivery.